Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | = 0.625 ug ml-1 | In vitro minimum inhibitory concentration of the compound against Crypteroccus neoformans | ChEMBL. | 10782684 |
MIC (functional) | = 0.625 ug ml-1 | In vitro minimum inhibitory concentration of the compound against Crypteroccus neoformans | ChEMBL. | 10782684 |
MIC (functional) | = 5 ug ml-1 | In vitro minimum inhibitory concentration of the compound against Candida albicans | ChEMBL. | 10782684 |
MIC (functional) | = 5 ug ml-1 | In vitro minimum inhibitory concentration of the compound against Candida albicans | ChEMBL. | 10782684 |
MIC (functional) | > 20 ug ml-1 | In vitro minimum inhibitory concentration of the compound against Aspergillus fumigatus | ChEMBL. | 10782684 |
Tail vein toxicity (ADMET) | Compound (at 20 mg/kg) was tested to induce tail vein irritation in mice; Negative | ChEMBL. | 10782684 | |
Tail vein toxicity (ADMET) | NT 0 | Compound (at 20 mg/kg) was tested to induce tail vein irritation in mice; Negative | ChEMBL. | 10782684 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.